News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

arGentis Pharmaceuticals, LLC Receives Favorable Opinion for European Orphan Drug Designation


1/6/2009 8:47:22 AM

MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency’s (EMEA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending the company’s product candidate ARG201 (native type 1 bovine collagen) for the treatment of diffuse systemic sclerosis, also known as systemic scleroderma (SSc) for designation as an orphan medicinal product to the European Commission.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES